Top Markets
Coin of the day
PhaseRx, Inc. PhaseRx, Inc.

PhaseRx, Inc.

PZRXQ
Rank in Stocks #42474
PhaseRx, Inc. is a biopharmaceutical company dedicated to developing treatments... PhaseRx, Inc. is a biopharmaceutical company dedicated to developing treatments for inherited enzyme deficiencies affecting the liver. Its therapeutic strategy involves intracellular enzyme replacement, powered by its unique Hybrid mRNA technology platform, which facilitates the production of absent enzymes directly within the body's cells. The company's pipeline includes several programs targeting urea cycle disorders, such as PRX-OTC for ornithine transcarbamylase deficiency, PRX-ASL for argininosuccinate lyase deficiency, and PRX-ASS1 for argininosuccinate synthetase deficiency. Established in 2006, PhaseRx is headquartered in Seattle, Washington.
Share Price
$0.0001
Last synced: 2026-08-11
Market Cap
$1.17K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade PhaseRx, Inc. (PZRXQ)

Category

Operating Margin for PhaseRx, Inc. (PZRXQ)
Operating Margin as of 2026 TTM: 0.00%
According to PhaseRx, Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for PhaseRx, Inc. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
38.97% -
US
28.81% -
NL
0.00% -
CH
31.23% -
BE
0.00% -
KR
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.